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included age = 49 years, disease duration = 9.5 years, TJC = 24,
SJC = 14, HAQ-DI = 1.0, and PASI = 7.9. Forty-four percent of
patients were female. Pearson correlation coefﬁcients between
variables were -0.6 (HAQ-DI and SF-6D, p < 0.05), -0.2 (PASI
and SF-6D, p < 0.05) and 0.1 (HAQ-DI and PASI, p = 0.2) As
determined by multiple linear regression, signiﬁcant independent
predictors of PsA-related QoL (in descending order of impor-
tance) were: functional loss (HAQ-DI), severity of psoriasis
(PASI), and TJC (all p < 0.05). SJC was not a signiﬁcant predic-
tor of QoL in PsA. CONCLUSIONS: In patients with PsA, the
main determinants of QoL measured were degree of disease-
related functional loss and severity of skin disease. In contrast to
ﬁndings in rheumatoid arthritis, joint counts were of secondary
importance. These ﬁndings have important implications for eco-
nomic evaluations of new treatments for PsA.
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OBJECTIVE: the management of hemophilic patients is very
expensive. This situation becomes extreme when patients
develop inhibitors, which comprises the effectiveness of treat-
ment, with potential increase of morbidity and mortality. We
compared cost of care and Health-Related Quality-of-Life
(HRQoL) between hemophilic patients with (INHIB+) and those
without (INHIB-) inhibitors. METHODS: INHIB+ was enrolled
in the Cost Of Care Inhibitors Study (COCIS) [Gringeri et al,
Blood 2003]; INHIB- was enrolled in the Cost Of Care of
HEmophilia (COCHE) study: naturalistic, multicentre, longitu-
dinal studies involving patients enrolled at the Italian Hemo-
philia Centres. Results are reported on: cost with clotting factor
concentrates evaluated from the Italian National Health Service’s
point of view, HRQoL evaluated with the EuroQol and Short
Form-36. The bootstrap resampling method (5000 samples) was
applied as a statistical approach to compare the two groups.
RESULTS: INHIB+ was 52: median age 35 years (15–64), 100%
with hemophilia A, 94.2% with severe hemophilia, 98% high
responders. INHIB- was 232: median age 34.3 years (18–74),
86.6% with hemophilia A, 72.4% with severe hemophilia.
Patients with inhibitors bled signiﬁcantly less frequently than
patients without inhibitors (p < 0.0001): INHIB+ reported on
average 0.59 hemorrhages/patient/month to joints and muscles
(median = 0.33, 0–2.61), INHIB- had 2.10 hemorrhages/
patient/month (median = 1.44, 0–26.0). On average 0.16 chirur-
gical interventions/patient/year were performed to INHIB+
(19.2% patients involved), 0.35 interventions/patient/year were
performed to INHIB- (16.4% patients involved). Overall, cost
of care for INHIB+ was 17.725 €/patient/month; cost for
INHIB- was 8.341 €/patient/month, 16.473 €/patient/month to
treat patients on prophylaxis and 4.2 to treat those on demand
regimen. in the two groups HRQoL was similar, concerning both
the physical and mental components. CONCLUSION: treatment
for INHIB+ patients is much more costly than that for INHIB-
patients, is effective and allows reaching good levels of HRQoL,
similar to those perceived by INHIB- patients.
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OBJECTIVES: Information on costs of multiple myeloma (MM)
management is scarce. The objective of this incidence–based
cost–of–illness study was to assess direct medical costs and cost
drivers in major disease phases: primary diagnosis (PD), recur-
rent (RCD) or refractory disease (RFD). METHODS: A retro
projected chart review was performed in 9 centres (n = 176, ran-
domly selected patients) in Belgium (n = 56), France (n = 41),
UK (n = 40) and Germany (n = 39). Costs were calculated from
the payer’s perspective by multiplying resource utilization with
local unit costs from ofﬁcial sources. Data collection covered the
2–year period (or up to death) following treatment initiation in
2001. Descriptive statistics were performed on costs. Cost
drivers were identiﬁed using a linear mixed regression model.
RESULTS: The sample included 49% PD, 41% RCD and 10%
RFD. Stem–cell or bone marrow transplantation rate was 52%.
For PD, RCD and RFD respectively, 2–year costs were €59,648,
€47,039 and €46,362, of which approximately 80% incurred
during the ﬁrst year. Transplantation rates differed between
countries (39%–73%) and disease phase (68%, 40% and 28%
in PD, RCD and RFD). Descriptive cost analysis showed poten-
tial impact of phase, survival, transplantation and centre. The
regression model suggested costs to increase with number of
transplantations (p < 0.0001), increasing stage at diagnosis (p =
0.0097), occurrence of complications (p = 0.0194) and decreas-
ing age (p = 0.0004). The mean total cost was €31,612
(€26,300–€34,300) in patients without transplantation com-
pared to €59,915 (€53,000–€66,600) in the transplant popula-
tion. CONCLUSION: The study provided insight into cost
drivers in MM. The main therapeutic cost driver was transplan-
tation. Important centre–speciﬁc variation exists in transplanta-
tion accessibility. In addition, there is a lack of consensus on
transplantation practices. Since the current study was undersized
to represent national transplantation rates, further research is
needed to establish real life transplantation rates in different MM
settings.
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OBJECTIVE: To estimate the current and future economic
burden of Overactive Bladder (OAB) in males in ﬁve European
countries. METHOD: A cost of illness model estimated the
annual cost of managing OAB in Germany, Italy, Spain, Sweden
and the UK by deﬁning a locally relevant package of care and
multiplying resources used by country-speciﬁc unit cost data.
The total cost of OAB in males was calculated by multiplying
the estimated prevalence of OAB in males by the estimated
annual direct cost of OAB management. The model also esti-
mated the likely economic impact of increasing numbers of
elderly men. RESULTS: The prevalence of OAB is known to be
highest in the elderly and is commonly perceived to affect mostly
women. However, in this study, 9.6m males aged >40 were esti-
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mated to currently suffer from OAB across the ﬁve countries. An
estimated 2.5m also have symptoms of urge incontinence. By
2020, 2.1m additional males are expected to be affected by
OAB. The average health care cost associated with managing
these patients ranged from €200 in the UK to €732 in Italy. The
total cost of OAB in males aged >40 were estimated to be €1.7
billion in 2005: €412m in Germany; €607m in Italy; €350 in
Spain; €71m in Sweden and €231 in the UK. By 2020, the total
cost of OAB in males is expected to increase to €2 billion. This
compares with a total burden of €4.1 billion in 2005 and pro-
jected total burden of €5.2 billion in 2020. DISCUSSION: The
burden of OAB in males was 40% of the total burden in the
overall population aged > 40. The economic burden is likely 
to increase in line with our prevalence forecasts. Since many
males do not seek treatment, the future cost burden may be
underestimated.
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OBJECTIVE: To determine characteristics related to lost pro-
ductivity in working adults with overactive bladder (OAB) using
data from a large US multicenter trial. METHODS: Baseline data
were obtained from 2770 participants in the Multicenter Assess-
ment of Transdermal Therapy in Overactive Bladder with Oxy-
butynin (MATRIX). Productivity was assessed using the Work
Productivity Questionnaire (WPQ), a modiﬁed version of the
Work Limitations Questionnaire (WLQ) which captures physi-
cal, mental (concentration), time (interruptions and adherence to
a schedule), and output (ability to handle workload) domains
related to work productivity. Additional questions on demo-
graphics, prior OAB treatment, and daily pad use were asked. A
WPQ Index was computed to estimate productivity impairment
compared to healthy individuals. Characteristics related to pro-
ductivity loss were determined using group comparisons (t-test).
RESULTS: Approximately half (52.7%) of participants were of
working age (18–64 years), and 44.9% were employed. The
majority were female (92.0%) and white (81.2%). Overall,
working participants were approximately 7.9% less productive
than healthy individuals. Group comparisons revealed that
females experienced greater physical limitations than males (p <
0.05) but had similar time, mental, and output scores. Age
younger than 65 was associated with greater impairments of
time, mental, and output domains (p < 0.05 for all). Minorities
(African Americans, Hispanics, and Asians) experienced signiﬁ-
cantly less productivity than whites across all categories with the
exception that African Americans reported similar time impair-
ments to whites. Productivity scores were inversely related to
daily pad use (those using 1- or 2- experiencing higher scores
than those using 3 or more), and did not differ between treat-
ment naïve and those previously treated (p > 0.05 for all
domains). CONCLUSIONS: OAB causes job interruptions, dif-
ﬁculties in adhering to a schedule, physical limitations, impaired
concentration, and reduced ability to handle workload. Females
with OAB experience more physical limitations than males, and
minorities generally experience greater productivity impairments
than whites.
Podium Session II
Health Care Use and Policy: Focus on Health 
Professionals
HP1
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OBJECTIVES: To identify predictors of off-label utilization of
Erythropoietin and Darbepoetin across hospitals in the United
States. METHODS: A retrospective database (Solucient®) review
was performed on 169,288 discharged patients who received ery-
thropoietin and darbepoetin across 187 hospitals. Based upon
an evidence-based medicine framework, utilization of the two
drugs was categorized as “on-label” (approved by the FDA),
“off-label-supported” (not FDA-approved but with strong evi-
dence supporting off-label use), and “off-label-unsupported”
(minimal literature support for off-label indications). A multin-
omial logistic regression model clustered by hospitals was used.
Model covariates were patient demographics, clinical outcomes,
physician specialty, hospital size, teaching status, region, drug
dose, and number of administrations. RESULTS: Relative to on-
label, physician specialty, patient age group, race, and drug cov-
erage were signiﬁcant (at the 0.05 level) predictors of off-label
use (supported and unsupported). Surgeons were twice as likely
to prescribe off-label-unsupported (OFUS) than generalists 
and four times more likely than specialists. Infants (0–1 years),
{RRR-164; 95%CI, 84–319}, children (1–17 years), {RRR-2.30;
95%CI, 1.45–5.0}, and young-adults (18–24 years) {RRR-2.30,
95%CI, 2.07–3.19} were more likely to receive OFUS compared
to middle-aged adults (40–59 years), while OFUS prescribing 
for individuals over 75 years was weakly predictive (RRR-1.28;
95%CI, 1.03–1.6). African-Americans and Native-Americans
were twice as likely to receive drugs for off-label-supported
(OFS) but half as likely for OFUS use relative to whites. More-
over, Title-V, Worker’s compensation, and self-pay patients were
more likely to receive OFUS. CONCLUSIONS: Variations in off-
label prescribing among physician specialties may reﬂect a lack
of consensus on practice guidelines. The common use of OFUS
prescribing in pediatrics may be explained by the limited clini-
cal trial data on children. Racial differences in OFUS may indi-
cate differing disease prevalence in populations. Knowing causes
of off-label prescribing can help decision makers understand the
degree to which it is appropriate.
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OBJECTIVES: We implemented a focused drug therapy man-
agement intervention aimed at reducing polypharmacy for Med-
icaid recipients in North Carolina nursing homes. Targeted were
patients receiving >18 prescriptions in 90 days. During sched-
uled monthly home visits, consultant pharmacists providing
routine drug regimen reviews also reviewed drug proﬁles dis-
playing claims-generated drug problem alerts. Pharmacists doc-
umented reviews, recommendations and resulting drug therapy
changes. Study objectives were to determine: 1) the frequency
with which potential drug therapy problems (PDTPs) were found
